Association of High Prolactin Level on Postoperative Day 1 and Tumor Invasion with Female Gonadal Dysfunction After Trans-Sphenoidal Surgery of Pituitary Adenomas

Background The aim of this study was to evaluate the risk factors of gonadal dysfunction among Chinese women of reproductive age with pituitary adenomas (PAs) after trans-sphenoidal surgery. Material/Methods We retrospectively evaluated 317 women (16–44 years old) who underwent gonadal function and hormone testing before and after trans-sphenoidal surgery for PAs during 2003–2012. Gonadal function was assessed on the basis of menstrual status. Results Three women were excluded because of pre-existing gynecological diseases. Before trans-sphenoidal surgery, 34 (10.7%) women were eugonadal and 283 (89.3%) women had gonadal dysfunction. After trans-sphenoidal surgery, 130/189 (68.7%) women with follow-up menstruation data were eugonadal, and 59/189 (31.2%) women exhibited gonadal dysfunction. In addition, 67.4% women of reproductive age with PAs and gonadal dysfunction were restored by trans-sphenoidal surgery (P<0.01). Postoperative gonadal dysfunction was independently associated with high prolactin level at day 1 after trans-sphenoidal surgery (odds ratio (OR)=1.024; 95% confidence interval (CI)=1.005–1.043; P=0.012) and tumor invasion (OR=5.752; 95%CI=1.618–20.447; P<0.01). Based on the receiver operating characteristic (ROC) curve, prediction of gonadal dysfunction in women of reproductive age after trans-sphenoidal surgery for PAs using prolactin >46.82 μg/L on postoperative day 1 had sensitivity of 88%, specificity of 95%, positive predictive value of 98%, and negative predictive value of 76%, and an area under the ROC curve of 0.701. Conclusions Gonadal dysfunction is very common in Chinese women of reproductive age with PAs and can be effectively restored by trans-sphenoidal surgery. Prolactin >46.82 μg/L at 1 day after trans-sphenoidal surgery and tumor invasion can predict postoperative gonadal dysfunction in these patients.

[1]  P. Chanson,et al.  Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database , 2017, Endocrine-related cancer.

[2]  V. Steinthorsdottir,et al.  The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. , 2015, European journal of endocrinology.

[3]  J. Eloy,et al.  Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges , 2015, Journal of Clinical Neuroscience.

[4]  B. Bidzińska-Speichert,et al.  Ovarian Hyperstimulation Caused by Gonadotroph Pituitary Adenoma--Review. , 2015, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[5]  D. Grattan 60 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-prolactin axis , 2015, The Journal of endocrinology.

[6]  A. Herbison,et al.  Prolactin Regulation of Kisspeptin Neurones in the Mouse Brain and its Role in the Lactation‐Induced Suppression of Kisspeptin Expression , 2014, Journal of neuroendocrinology.

[7]  M. Korbonits,et al.  Epidemiology and etiopathogenesis of pituitary adenomas , 2014, Journal of Neuro-Oncology.

[8]  L. Nachtigall,et al.  Current treatment options for hyperprolactinemia , 2013, Expert opinion on pharmacotherapy.

[9]  W. Inder,et al.  Gender differences in presentation and outcome of nonfunctioning pituitary macroadenomas , 2013, Clinical endocrinology.

[10]  Jacques Young,et al.  Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. , 2012, The Journal of clinical investigation.

[11]  S. Ezzat,et al.  Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature , 2012, Clinical endocrinology.

[12]  M. Molitch Prolactinoma in pregnancy. , 2011, Best practice & research. Clinical endocrinology & metabolism.

[13]  D. Unuane,et al.  Endocrine disorders & female infertility. , 2011, Best practice & research. Clinical endocrinology & metabolism.

[14]  P. Chanson,et al.  Female gonadal function before and after treatment of acromegaly. , 2010, The Journal of clinical endocrinology and metabolism.

[15]  K. Kovacs The 2004 Who classification of pituitary tumors: comments , 2005, Acta Neuropathologica.

[16]  D. Schoenfeld,et al.  Hypogonadism in patients with acromegaly: data from the multi‐centre acromegaly registry pilot study , 2001, Clinical endocrinology.

[17]  J. J. Mukherjee,et al.  Menstrual irregularity in women with acromegaly. , 1999, The Journal of clinical endocrinology and metabolism.

[18]  A. Grossman,et al.  Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. , 1998, The Journal of clinical endocrinology and metabolism.

[19]  F. Doyle,et al.  The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours. , 1982, The Quarterly journal of medicine.